NEW YORK, NY / ACCESS Newswire / November 14, 2025 / For decades, sustainability lived in the realm of aspiration. Ambitious global gatherings promised breakthroughs, governments drafted sweeping resolutions, and industries delivered polished reports declaring progress. Yet, beneath the speeches and statistics, a structural flaw persisted: none of these systems could verify themselves. Targets depended on trust. Compliance depended on declarations. Safety depended on assumptions.
It was a world built on optimism rather than evidence, and eventually the gap became impossible to ignore. When commitments outpaced the ability to confirm them, global sustainability stalled-not for lack of will, but for lack of tools.
SMX (NASDAQ:SMX) is rebuilding the foundation. Instead of asking the world to trust claims, it gives materials the ability to prove themselves. Its molecular-level identity technology transforms plastics, composites, and flame-retardant products into verifiable data sources, allowing policies to function not as promises, but as measurable realities. In this model, sustainability stops being a narrative. It becomes a system that cannot lie.
The End of Assumptions, the Rise of Evidence
The reason sustainability faltered was not ignorance; it was invisibility. Regulators couldn’t see inside materials. Manufacturers couldn’t verify recycled content beyond paperwork. Safety authorities couldn’t confirm whether flame retardants were present or effective until after failures occurred.
SMX removes that blindness by embedding an invisible chemical signature directly into products at the molecular level. This identity survives processing, melting, shredding, and recycling. A quick scan reveals composition, origin, and compliance with a level of precision that renders old reporting models obsolete.
It is not oversight. It is an embedded truth. And it allows regulations to stop relying on self-policing, because materials can now carry their own evidence.
Where Reality Replaces Reporting
Singapore offers the clearest example of this shift. Working with A*STAR, SMX is building a plastics passport that links every item to a verified record of its own lifecycle. This system doesn’t ask companies what they recycled. It shows them. It shows regulators. It shows auditors. It shows the market.
In Europe, SMX’s planned collaboration with REDWAVE takes this one step further by integrating verification into production itself. The conveyor line becomes an enforcement mechanism. Each unit of material is validated in real time, creating a live reflection of compliance rather than a quarterly or annual claim.
And in North America, SMX’s work with the North American Flame Retardant Alliance introduces a safety framework rooted in measurable chemistry instead of paperwork. Regulators can finally confirm compliance inside the product, not after an incident. This turns safety into a proactive discipline rather than a forensic one.
The First System Where Materials Themselves Are the Source of Truth
With SMX’s technology embedded directly into products, enforcement is no longer adversarial. It becomes automatic. Manufacturers gain clarity rather than fear. Regulators move from policing to monitoring. Insurers get quantifiable risk instead of actuarial speculation. Consumers receive goods backed by data instead of marketing language.
In this system, sustainability is not an opinion. It is a reading. Safety is not a claim. It is a measurable property. Recycling is not a pledge. It is a trail of evidence.
Global promises failed because the world lacked visibility. SMX is rebuilding the sustainability framework with reality baked in, molecule by molecule. It is turning the physical world into a trustworthy one-not through speeches, but through chemistry.
The shift is already underway. And the future of sustainability will not be written on paper. It will be written inside the materials themselves.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements involve risks, uncertainties, and assumptions about future events related to SMX (NASDAQ:SMX), its molecular marking technologies, and their potential adoption across regulatory, industrial, and commercial environments.
Forward looking statements in this editorial include, without limitation, expectations regarding the scalability, performance, and market acceptance of SMX’s molecular identification systems; anticipated outcomes of its collaborations with A*STAR in Singapore, REDWAVE in Europe, and the North American Flame Retardant Alliance; the potential for SMX technology to enhance or replace existing verification, recycling, or safety frameworks; and assumptions about regulatory trends, sustainability mandates, industrial traceability standards, and demand for material-level authentication in global supply chains.
These statements are based on current assumptions and projections, which are subject to numerous risks and uncertainties, including changes in regulatory requirements, geopolitical conditions, supply-chain volatility, competitive technologies, partner implementation risks, operational challenges, and factors outlined in SMX’s filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Readers are cautioned that actual results may differ materially from those indicated in forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect future events or new information, except as required by law.
Through personalized, evidence-based programs, the Boynton Beach facility continues its mission to help individuals overcome addiction and rebuild their lives.
BOYNTON BEACH, FL / ACCESS Newswire / November 13, 2025 / Bright Futures Treatment Center is proud to announce a major milestone – more than 12,000 patients treated through its addiction and mental health recovery programs. This achievement reflects years of consistent work across Florida to provide real support for people facing substance use disorders and co-occurring mental health conditions. Located in Boynton Beach, the center serves individuals from across the region who are ready to take the next step toward long-term recovery. Each patient treated represents a personalized plan of care, designed to meet real-life needs and deliver lasting change. This number is more than a statistic. It shows how the center continues to make a real difference in people’s lives through direct, evidence-based treatment.
A Personalized Approach That Drives Results
The programs behind this milestone combine structured treatment methods with flexible care plans that adjust to each person’s needs. At Bright Futures Treatment Center, patients receive support through a combination of medically assisted treatment, dual diagnosis care, and wellness-based services. These methods work together to help people manage substance use and address related mental health conditions such as anxiety, depression, or trauma.
The medical team uses approved medications to reduce cravings and withdrawal symptoms, making the early stages of recovery more manageable. Alongside this, licensed professionals provide therapy for both addiction and mental health, recognizing how these issues often overlap. Physical activity, nutrition guidance, and mindfulness sessions round out the program to support overall stability.
Each person gets a treatment plan designed for their situation, background, and goals. This flexible model reflects the center’s long-standing message – building brighter futures is possible when recovery is personal, structured, and consistent.
A Mission Rooted in Real Transformation
Every milestone tells a story of dedication, and for Bright Futures Treatment Center, that story revolves around transformation. The team continues to remind patients that recovery is more than abstinence-it’s a full renewal of body, mind, and purpose. Staff members describe their mission as helping people rebuild confidence, restore self-worth, and reconnect with life in meaningful ways.
This approach reflects the center’s guiding belief that “recovery means creating a life worth living,” as expressed in their mission statement. The message applies to every patient who walks through their doors. It drives staff to go beyond clinical care and focus on practical progress, accountability, and emotional healing.
The organization operates on the principle that successful treatment depends on continuous guidance and a real human connection. The staff provides structure, motivation, and education so that each person develops long-term tools for success. They view recovery as a team effort that extends beyond the program’s walls, encouraging patients to carry what they learn into daily life.
In line with that vision, Bright Futures continues to expand programs that promote lasting recovery through evidence-based therapy, community involvement, and aftercare planning. “Our mission is not just treatment – it’s transformation,” the team often emphasizes. This statement captures what the center stands for: turning the process of recovery into a pathway toward lasting change, independence, and hope.
Lighting the Path Ahead
Bright Futures Treatment Center continues to support recovery by working with insurance providers, expanding access to care, and developing new program features based on patient feedback. The team remains focused on helping people build stable, long-term outcomes. As they mark the 12,000-patient milestone, their goal stays the same: to provide real tools, personalized care, and a clear path forward for anyone ready to begin recovery. Every step taken today helps light the pathway for those who come next.
Bio: Alex Alonso is a Chief Operating Officer with extensive experience in behavioral health and addiction treatment management. He specializes in developing patient-centered programs that combine evidence-based practices with organizational efficiency. Through his work, Alex focuses on improving access to quality care and supporting long-term recovery.
Company plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter ended September 30, 2025
SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, November 17, 2025, at 8:30 a.m. Eastern to review third-quarter 2025 financials and provide corporate updates.
Participation Instructions for Jaguar Investor Webcast
When: Monday, November 17, 2025 at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that Jaguar will file its 10-Q on November 14, 2025 for the quarter ended September 30, 2025, and the expectation that Jaguar will hold an investor webcast on November 17, 2025. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
BOCA RATON, FLORIDA / ACCESS Newswire / November 14, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN), a Berachain-focused digital asset treasury company and global seller of premium cannabis accessories, today reported its financial results for the third quarter and nine months ended September 30, 2025 along with an update on the expansion of the Company’s Berachain (BERA) treasury strategy.
BERA is the fee token of Berachain, the first Layer 1 blockchain powered by Proof of Liquidity (PoL) to help businesses scale and power on-chain economies. PoL provides BERA with a staking yield derived from the revenues or ownership of companies on the network.
In late October 2025, Greenlane executed a strategic shift – adopting a treasury reserve strategy with BERA as the Company’s primary asset. Greenlane’s goal is to give investors a simplified way to participate in what management believes will be Berachain’s transformation of global finance, with institutional-grade discipline, transparency, and full activation of Berachain’s yield potential. Greenlane is strategically accumulating BERA and employing active treasury management and staking. The result is yield-generating BERA treasury that aims to compound growth and capture the full upside exposure of BERA.
While the Company advances its digital-asset strategy and treasury operations, it will continue to operate its distribution business, enhance operational efficiencies and continue inventory monetization to accelerate the disposition of aged inventory.
Key Highlights Since Launch of BERA Treasury Strategy
Built world class leadership team:
Bruce Linton, previously led Canopy Growth Corporation to a $15B market capitalization and has extensive experience in leading companies across communications and cleantech, joined as Chairman of the Board.
Billy Levy, a serial entrepreneur and capital markets executive with a history of building, scaling, and exiting companies across multiple industries, including co-founding Virgin Gaming in collaboration with Sir Richard Branson, appointed as a director.
Ben Isenberg, appointed as Chief Investment Officer to manage the BERA treasury strategy. Isenberg also serves as Founder and Principal of BSQD Corp., a market-making and proprietary trading firm specializing in digital assets and cryptocurrencies. In this role, Mr. Isenberg is responsible for the strategic direction and oversight of digital asset trading operations. Prior to this, Isenberg served as a Trader at Tradias GmbH, a BAFIN regulated market maker based in Frankfurt, Germany from 2021- 2024. Before entering the digital asset markets, Isenberg worked in investment banking at M Partners in Toronto, where he covered digital assets, technology and mining from 2019-2021.
Formed a Digital Assets Committee in October 2025 comprised of Mr. Levy and Mr. Linton, with Mr. Linton serving as chair.
Establishing an experienced team of institutional-grade capital markets and treasury management professionals to operationalize the Company’s strategy with support from leading crypto asset managers and custodians.
Raised over $110 million in capital and digital assets through an October 23, 2025 private placement offering to drive BERA acquisitions, resulting in approximately $24.3 of net cash proceeds, approximately $19.0 of stablecoin proceeds, and approximately 54.2 million BERA.
The Company intends to manage its BERA tokens to generate yields through staking and activities and to enhance long-term value as the adoption of the BERA token increases.
Third Quarter 2025 Results Compared to Prior Year Period
Total revenue of premium cannabis accessories, vape devices, and lifestyle products was $0.74 million compared to $4.0 million in the prior year period.
Total operating expenses were $4.0 million, compared to $3.6 million in the prior year period.
Net loss was $8.9 million compared to a net loss of $3.8 million in the prior year period.
Management completed a comprehensive review of inventory aging and realizability in connection with the Company’s transition under the BERA initiative toward a capital-light, IP-driven operating model. As a result, the Company recorded a $5.0 million non-cash inventory reserve, included in cost of sales, to reflect expected recoveries from legacy product lines.
As of September 30, 2025, the Company had cash and cash equivalents of $1.8 million and no borrowings outstanding.
Subsequent Events
On October 23, 2025, we closed a $110.7 million private placement consisting of cash and crypto-denominated subscriptions, as disclosed in our Form 8-K filed October 20, 2025. The closing delivered approximately $24.3 million of net cash proceeds and approximately $19.0 million of stablecoin proceeds and resulted in holdings of approximately 54.2 million BERA as of October 23, 2025. These proceeds strengthen near-term liquidity as we execute a strategic shift from the legacy business and transition to our digital-asset treasury model.
GREENLANE HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts)
September 30, 2025
December 31, 2024
(unaudited)
ASSETS
Current assets
Cash
$
1,810
$
899
Accounts receivable, net of allowance of $3,383 and $2,616 at September 30, 2025 and December 31, 2024, respectively
4,138
4,262
Inventories, net
6,250
14,215
Vendor deposits
64
3,091
Other current assets
2,080
1,305
Total current assets
14,342
23,772
Property and equipment, net
1,101
1,420
Operating lease right-of-use assets
300
1,043
Other assets
1,895
2,396
Total assets
$
17,638
$
28,631
LIABILITIES
Current liabilities
Accounts payable
$
4,066
$
9,787
Accrued expenses and other current liabilities
1,555
1,218
Customer deposits
684
2,661
Current portion of notes payable
–
7,674
Current portion of operating leases
319
926
Total current liabilities
6,624
22,266
Operating leases, less current portion
1
83
Total liabilities
6,625
22,349
Commitments and contingencies (Note 7)
–
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding
–
–
Class A common stock, $0.01 par value per share, 600,000,000 shares authorized, 1,386,551 and 3,023 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively*
–
–
Class B common stock, $0.0001 par value per share, 30,000,000 shares authorized, and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024*
–
–
Common stock, value
–
–
Additional paid-in capital*
301,841
281,095
Accumulated deficit
(290,944
)
(274,929
)
Accumulated other comprehensive income
265
265
Total stockholders’ equity attributable to Greenlane Holdings, Inc.
11,162
6,431
Non-controlling interest
(149
)
(149
)
Total stockholders’ equity
11,013
6,282
Total liabilities and stockholders’ equity
$
17,638
$
28,631
*
After giving effect to the Reverse Stock Splits
GREENLANE HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share amounts)
Three months ended September 30,
Nine months ended September 30,
2025
2024
2025
2024
Net sales
$
737
$
4,038
$
2,994
$
11,616
Cost of sales
5,840
1,011
7,374
6,066
Gross profit (loss)
(5,103
)
3,027
(4,380
)
5,550
Operating expenses:
Salaries, benefits and payroll taxes
1,462
1,609
3,848
6,066
General and administrative
1,956
1,771
6,550
6,864
Restructuring expenses
492
–
492
–
Depreciation and amortization
87
185
394
635
Total operating expenses
3,997
3,565
11,284
13,565
Loss from operations
(9,100
)
(538
)
(15,664
)
(8,015
)
Other income (expense), net:
Interest expense
(2
)
(3,219
)
(393
)
(4,030
)
Change in fair value of contingent consideration
–
–
–
1,000
Gain on extinguishment of debt
–
–
–
2,166
Other income (expense), net
169
–
42
(3
)
Total other income (expense), net
167
(3,219
)
(351
)
(867
)
Loss before income taxes
(8,933
)
(3,757
)
(16,015
)
(8,882
)
Provision for (benefit from) income taxes
–
–
–
–
Net loss
(8,933
)
(3,757
)
(16,015
)
(8,882
)
Less: Net income (loss) attributable to non-controlling interest
–
–
–
(17
)
Net loss attributable to Greenlane Holdings, Inc.
$
(8,933
)
$
(3,757
)
$
(16,015
)
$
(8,865
)
Net loss attributable to Class A common stock per share – basic and diluted (Note 9)*
$
(6.44
)
$
(5,484.67
)
$
(19.88
)
$
(12,044.84
)
Weighted-average shares of Class A common stock outstanding – basic and diluted (Note 9)*
1,386,551
685
805,484
736
Other comprehensive income (loss):
Foreign currency translation adjustments
–
4
–
3
Comprehensive loss
(8,933
)
(3,753
)
(16,015
)
(8,879
)
Less: Comprehensive loss attributable to non-controlling interest
–
–
–
(17
)
Comprehensive loss attributable to Greenlane Holdings, Inc.
$
(8,933
)
$
(3,753
)
$
(16,015
)
$
(8,862
)
*
After giving effect to the Reverse Stock Splits
GREENLANE HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands)
Nine Months Ended September 30,
2025
2024
Cash Flows from Operating Activities:
Net loss
$
(16,015
)
$
(8,882
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
394
635
Equity-based compensation expense
–
86
Change in fair value of contingent consideration
–
(1,000
)
Accretion of debt discount
284
3,373
Gain on extinguishment of debt
–
(2,166
)
Change in provision for credit losses
767
41
Changes in operating assets and liabilities:
Accounts receivable
(643
)
(660
)
Inventories
7,965
4,516
Vendor deposits
3,027
40
Other current assets
(219
)
1,058
Accounts payable
(5,721
)
(1,221
)
Accrued expenses and other liabilities
336
468
Customer deposits
(1,977
)
(1,520
)
Net used in operating activities
(11,802
)
(5,232
)
Cash flows from Investing Activities:
Purchases of property and equipment, net
(75
)
(173
)
Net cash used in investing activities
(75
)
(173
)
Cash flows from Financing Activities:
Proceeds from issuance of Class A common stock and warrants
20,746
5,640
Proceeds from exercise of stock options, net of costs
1,477
Proceeds from notes payable
–
2,950
Payments on notes payable
(7,958
)
(2,100
)
Proceeds from future receivables financing
–
225
Repayments of loan against future accounts receivable
–
(939
)
Other
–
(5
)
Net cash provided by financing activities
12,788
7,248
Effects of exchange rate changes on cash
–
3
Net increase in cash
911
1,846
Cash as of beginning of the period
899
463
Cash as of end of the period
$
1,810
$
2,309
About Greenlane Holdings, Inc.
Founded in 2005, Greenlane is a premier global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. We operate as a powerful family of brands, third-party brand accelerator, and an omnichannel distribution platform. The Company has entered the cryptocurrency industry and cash management of assets through a digital asset treasury strategy. For more information on Greenlane’s treasury strategy and future developments, visit https://investor.gnln.com.
This press release contains statements that constitute “forward-looking statements” within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding the potential for and amount of additional cash proceeds from warrant exercises, use of proceeds from the announced PIPE, future announcements and priorities, expectations regarding management, market position, business strategies, future financial and operating performance, and other projections or statements of plans and objectives.
These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors-many of which are beyond the Company’s control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company’s ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; the market performance of BERA; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2025, its most recent Quarterly Report on Form 10-Q, and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Friday, November 14th, at 11:25am ET at the Pharma Partnering Summit 2025 held at the Hilton Boston Logan Airport in Boston, MA.
Event Information:
Event
NanoViricides Presentation at the Pharma Partnering Summit 2025 in Boston, MA
Time & Date
11:25 am to 11:45 am ET on Friday, November 14, 2025
Location
Hilton Boston Logan Airport, Boston, MA
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.
NanoViricides’ Current Antiviral Drugs Pipeline: NV-387, A Revolutionary Broad-Spectrum Antiviral with Multiple Indications
The Phase II clinical stage revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections. Over 90% of human pathogenic viruses use heparan sulfate features, which NV-387 copies and presents to fool the virus.
NV-387 is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle using the same features that the virus uses to infect cells.
Viruses cannot escape NV-387 despite all the changes in the field because the virus still needs to bind to heparan-sulfate like features in order to cause productive pathogenic infection. NV-387 presents copious amounts of these binding sites to the virus, thereby engulfing the virus particle. Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates.
This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.
NV-387 stands to combat viral infections where there is no current medical treatment available, including RSV for pediatrics, Measles, MPox, and others.
NanoViricides lead clinical stage drug candidate NV-387 is rapidly moving into Phase II clinical trial for the treatment of MPox in the Democratic Republic of Congo.
NV-387 for Influenza and Bird Flu
Additionally, NV-387 was found to be substantially superior to Tamiflu as well as Xofluza against Influenza virus in animal model studies of Influenza A/H3N2 lethal lung infection 1.
The H3N2 Influenza A virus, subclade K, currently circulating in the Northern Hemisphere already has several mutations that distinguish it from the subclade J strain included in this year’s Influenza vaccine. The mismatched vaccine is therefore expected to be less effective than if the circulating strain was the same as the vaccine strain. The circulating H3N2 strain is also thought to cause a more severe pathology 2. Efficacy of seasonal influenza vaccines against H3N2 strain, even when well matched, has been about half that for H1N1 subtype, in terms of protection against severe disease leading to hospitalization. Influenza seasonal vaccine efficacy in unmatched years has been reported to be as low as 11-17% 3.
Further, should Bird Flu H5N1 turn into a human outbreak, variants resistance to Tamiflu and Xofluza can be expected to generate rapidly 4. NV-387 would be the ideal drug to combat the resulting outbreak, epidemic or pandemic. The causative influenza virus would not be able to escape NV-387 5.
NV-387 for All Respiratory Viral Infections
A separate Phase II clinical trial for the evaluation of NV-387 as a first line therapy of any respiratory viral infection (NV-387 for the treatment of Viral Acute or Severe Acute respiratory Infections, Viral ARI/SARI) is being planned. Success in this clinical trial would enable NV-387 to become the first ever antiviral drug that can be prescribed by a physician based on symptoms, as an emperic therapy for respiratory viral infections, without having to test for which virus is causing the disease.
NV-387 would play in a market size of well over $20 Billion as a dominant player, if approved for such emperic therapy of viral ARI/SARI.
NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study. These studies prompted evaluation of NV-387 as a first line therapy of respiratory viral infections.
There is no treatment approved for RSV, an important disease for infants and children in early life, as well as for geriatric subjects.
NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
There is no treatment approved for MPox; tecovirimat (TPOXX) has failed clinical trials, and no results are available from the brincidofovir (TEMBEXA) clinical trial “MOSA”.
“For Smallpox bio-threat readiness, the USA remains without an effective drug because of deficiencies in the two drugs approved under animal rule 6,” asserted Anil Diwan, PhD, President of the Company, adding, “NV-387 is ready to fill this gap.”
US government acquisitions for smallpox drugs have been in the range of hundreds of millions of dollars.
Additionally, NV-387 has shown excellent effectiveness against Measles virus lethal lung infection in a humanized (hCD150+ knock-in) mouse model.
There is no treatment approved for Measles. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.
NanoViricides’ Robust Technology Platform Has Enabled a Broad Drugs Pipeline: HerpesViruses, HIV, Others
The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.
In addition to NV-387, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.
The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.
NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery
Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.
Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.
Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.
NanoViricides, Inc. (the “Company”) ( www.nanoviricides.com ) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
1 Tamiflu (Oseltamivir) – Roche. Xofluza (Baloxavir) – Shionogi, Roche. H5N1 bird flu viruses resistant to Oseltamivir have already occurred. Resistance to Xofluza occurred at a high frequency in its clinical trial.
3 Yegorov S et al., Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta- analysis of test-negative design studies, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2025.09.023
4 Influenza viruses generate variants by more mechanisms than most viruses: (a) by mutations, typically few and small changes in viral proteins; (b) by recombinations, wherein portions of its genomic strands are swapped between the strands derived from two different Influenza A viruses infecting the same cell; (c) by re-assortments, wherein entire genomic segment from one Influenza A virus is packaged into a different Influenza A virus in the same cell. Each complete Influenza A virus contains eight separate genomic RNA strands, giving it tremendous flexibility for “swapping” these segments and generating new variants. It is thought that all influenza A viruses causing outbreaks or pandemics among humans since the 1900s originated from strains circulating in wild aquatic birds through reassortment with other influenza strains (wikipedia, https://en.wikipedia.org/wiki/Influenza_A_virus ).
5 All Influenza viruses bind to HSPG (heparan sulfate proteoglycan) as the first “attachment receptor”, and thus are targeted by the drug NV-387. The viruses then gain proximity to cells, and latch onto the Sialylated glycoproteins on the cell surface which is called the “cognate receptor” that enables the virus to be taken inside the cell. The cognate receptor for Influenza viruses that remain infectious to birds is slightly different from the one that the virus would need to use for efficiently infecting human cells. However, just one or a few mutations would be required in the currently circulating H5N1 bird flu viruses to become efficient in human-to-human transmission. Two different clades of H5N1 are circulating, one in wild birds, infecting into poultry, and another in dairy cattle, infecting pets and animals that drink raw milk, bringing the threat closer to a potential pandemic than it has ever been since the late 1990s.
6 Tecovirimat (TPOXX) was approved under the US FDA Animal Rule, and is stockpiled by the US Government Strategic National Stockpile (SNS). However, Tecovirimat-resistant viruses develop with a single point mutation in the viral VP37 protein. It is illogical to believe that any terrorist attack would be from a non-resistant smallpox strain. Brincidofovir (Tembexa) was approved under the US FDA Animal Rule, and is stockpiled in SNS. Brincidofovir carries a black box warning due to increased mortality rates in another indication, causes elevation of liver damage-related markers, is a carcinogen, may cause embryonic or fetal harm, and may irreversibly impair fertility, according to its prescribing information, limiting its applicability as a drug to be used across all population in the case of a smallpox bio-terrorism event ( https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf .).
The veterans advocate, nationally known for his “Men’s Health’ cover and ‘Dancing with the Stars’ appearance, uses the sustained acoustic medicine device to help him stay fit and maintain his busy schedule.
TRUMBULL, CONNECTICUT / ACCESS Newswire / November 14, 2025 / U.S. Army veteran Noah Galloway’s journey has taken him from being gravely wounded in Iraq to the cover of Men’s Health magazine to a third-place finish on “Dancing with the Stars” and a role as a national veterans’ advocate. Galloway credits ZetrOZ System‘s sam® wearable ultrasound device for helping him manage his chronic pain and recover from years of overuse and training.
Galloway, the newest ambassador for sam®, was prescribed the device from his doctors at the Department of Veterans Affairs and has been pleased with the results.
“So many veterans and athletes deal with chronic pain and turn to medication because they don’t see another option. Tools like sam® give us control,” Galloway said. “It’s effective, safe, and helps the body heal naturally. That’s huge for anyone trying to stay active and live without being dependent on pills or surgery.”
Sustained acoustic medicine, provided by ZetrOZ Systems’ sam® device, is a continuous, multi-hour ultrasound therapy that penetrates soft tissue, reduces inflammation, improves circulation, and accelerates the natural healing process.
The sam® device has been proven effective in more than 20 Level 1-5 clinical studies and 40 peer-reviewed journal articles, and through over 3.7 million patient treatments. sam® is the only long-duration ultrasound device cleared by the U.S. Food & Drug Administration for home use.
“sam® is easy to use, portable, and allows me to target areas that need attention without relying on medication or long clinic visits,” Galloway said. “It keeps me in the game, which means I can stay consistent with my workouts and my speaking schedule.”
Galloway has been an active advocate for veterans since his return from Iraq. He was serving his second deployment with the 101st Airborne Division (Fort Campbell, Kentucky) when a roadside bomb explosion cost him his left arm and leg.
“Coming home was one of the hardest battles I’ve ever faced,” Galloway said. “Fitness became the tool that helped me rebuild, not just my body but my mind. The discipline, accountability, and resilience I learned in the military carried over into how I train and recover. It’s about adapting, not quitting. Every day I move my body is a reminder that I’m still here, and that’s something I’ll never take for granted.”
Now Galloway relies on sam® to help him recover more quickly from his workouts. “Recovery from a workout is just as important as the workout itself,” he said. “I deal with a lot of overuse on my right side, especially from training and the demands of prosthetics. sam® has been a big help.”
Galloway’s recovery has led to national prominence as a motivational speaker and advocate for veterans. “Becoming the first veteran and amputee on the cover of Men’s Health and being named their ‘Ultimate Guy’ was a huge honor because it represented more than a magazine cover. It was proof of what’s possible when you don’t give up. Competing on ‘Dancing with the Stars’ pushed me far outside my comfort zone and reminded me that vulnerability can be powerful.”
“But the most meaningful moments come when someone tells me that my story motivated them to get back up and fight through their own struggle. That’s what keeps me doing what I do.”
ZetrOZ Systems is the inventor of sustained acoustic medicine and a leader in healing innovations for sports medicine, developing FDA-cleared wearable bioelectronic devices to deliver sam® technology. Built on proprietary medical technology of 48 patents, ZetrOZ is the exclusive manufacturer of the sam® product line for treating acute and chronic musculoskeletal conditions.
NEW YORK, NY / ACCESS Newswire / November 14, 2025 / For decades, industries have treated physical goods and digital systems as separate worlds. Software evolved. Data evolved. Connectivity evolved. But the materials that power global trade remained static, unverifiable, and silent. SMX (NASDAQ:SMX) is changing that divide by creating something unprecedented: a global operating system for physical matter.
This operating system is not installed on servers or devices. It lives inside the materials themselves. Through molecular marking and data-linked identities, SMX enables plastics, metals, textiles, and recycled inputs to behave like governed, trackable assets rather than anonymous commodities.
Six major partnerships across three continents are now running on this new layer, turning raw materials into data-ready participants in the world economy. This is not an upgrade. It is a full redesign of how materials work. Or, better said, material efficiency.
Singapore Installs the Public Sector Layer
Singapore’s collaboration with SMX and A*STAR functions like the first national deployment of the operating system. The country is assigning persistent digital identities to plastics as they move through production, consumption, and reuse.
This is not a pilot or a proof of concept. It is equivalent to installing the OS at the governmental level, enabling recycling incentives, compliance schemes, and industrial reporting to operate on verified data rather than estimated inputs. Singapore becomes the first nation where materials can run natively on the SMX architecture.
Austria Turns Machines Into System Nodes
In Austria, SMX and REDWAVE are pulling industrial automation directly into the operating system. Sorting machines that once separated plastics by type can now read and validate identity on the fly, turning conveyor belts into verification nodes and transforming recycling lines into real-time data streams.
Instead of producing material that must later be questioned or audited, these facilities generate output that is certified at the moment of processing. When this verified material enters Tradepro’s distribution network in Miami, it flows seamlessly into U.S. supply chains that increasingly require documented recycled content as a condition of participation.
Spain Deploys the Industrial Layer
Through CARTIF, Spain is installing the operating system inside the industrial environments that shape Europe’s circular-economy ambitions. The collaboration embeds molecular identity into pilot facilities that support packaging, construction materials, renewable components, and recycling technologies.
These locations function as installation zones where SMX’s architecture is woven directly into European manufacturing workflows. In a region where proof is rapidly becoming mandatory, the operating system shifts from an optional enhancement to the foundation that enables companies to stay compliant and competitive.
Gold and Silver Receive System-Level Identity
The financial layer is established through trueGold and Goldstrom, bringing precious metals into the operating system for the first time. Gold and silver can now carry a molecular ID that persists through melting, casting, vaulting, and resale, allowing the metals to behave as authenticated digital objects rather than static commodities.
Refiners gain precision in tracking provenance, banks gain certainty when assessing collateral, and auditors gain clarity in verifying inventory and movement. After centuries of reliance on stamps, certificates, and trust, gold and silver become system-aware materials whose identities cannot be forged or lost.
France Installs the Consumer-Material Layer
CETI in France is integrating SMX identity into fibers and fabrics, giving the textile sector an operating system it has never had. For decades, fashion relied on labels, supplier declarations, and marketing narratives to explain where materials came from and how they were made. Now, identity is embedded at the fiber level itself, turning every thread into a carrier of verifiable truth. Sustainability claims become measurable rather than symbolic, fiber blends become certifiable rather than estimated, and recycled content becomes traceable with a level of precision the industry has never achieved.
This shift reaches far beyond compliance. It changes how brands design collections, how manufacturers qualify suppliers, and how retailers price goods tied to environmental performance. Investors gain access to datasets that withstand scrutiny, and regulators gain a mechanism to enforce standards without relying on voluntary disclosures. Consumers, meanwhile, gain something the fashion world has always promised but rarely delivered: transparency they can trust.
As identity becomes inseparable from the fabric, textiles stop living in the realm of slogans and start functioning as proof-bearing products. The result is a consumer-material layer in which every garment participates in the broader verification ecosystem, carrying its history, composition, and integrity throughout its lifecycle.
A Global Operating System Takes Shape
Each partnership adds a new layer to the operating system, and together they form a structure that behaves like a digital stack for the physical world. Singapore establishes the national layer, proving that a country can run its plastics economy on verified material identity rather than assumptions. In Austria and the United States, REDWAVE and Tradepro expand the system into the industrial and commercial layers, where machinery and distribution channels begin treating materials as certifiable data instead of anonymous inputs.
Spain’s CARTIF contributes to the regulatory layer, ensuring that verification becomes inseparable from European circular-economy standards and compliance frameworks. Goldstrom adds the financial layer by giving gold and silver a molecular identity that functions like a secure credential inside the metals market. And in France, CETI completes the consumer layer by weaving identity directly into the textiles people wear, buy, recycle, and return to the value chain.
Layer by layer, the operating system becomes fully dimensional, spanning nations, factories, regulators, investors, and consumers until the entire material world begins operating on the same foundation of verified truth.
As these layers link together, the world shifts from unverifiable supply chains to authenticated material ecosystems. The OS becomes self-propelling. Adoption accelerates because verified materials outperform unverifiable ones. Compliance becomes simpler. Fraud becomes harder. Waste becomes measurable. Value becomes traceable.
SMX is not simply scaling a technology. It is installing a global operating system for how physical materials participate in commerce. And for the first time, the world is ready to run on it.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
This editorial contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not historical facts and reflect current expectations, hopes, beliefs, intentions, or strategies regarding future events. Words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying terms.
Forward-looking statements in this editorial include, for example, statements regarding SMX’s partnership activities in Singapore, Europe, and the United States, the development and expansion of its molecular marking technology, the potential creation and growth of an Internet of Materials, expected benefits from collaborations with A*STAR, REDWAVE, Tradepro, CARTIF, Goldstrom, and CETI, the potential for national and industrial-scale implementation of SMX systems, the anticipated role of molecular traceability in global supply chains, and expectations relating to SMX’s future products, services, growth strategy, commercial adoption, and technology roadmap.
These forward-looking statements are based on information available as of the date of publication and reflect current expectations, forecasts, assumptions, and judgments. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and factors that could cause actual results to differ materially from those expressed or implied.
Factors that may cause actual results to differ include changes in applicable laws or regulations, the ability of SMX and its partners to successfully develop, deploy, and commercialize molecular verification technologies, the timing and success of integration into manufacturing and recycling systems, market acceptance of SMX’s solutions, industry adoption rates for traceability and digital passport systems, the ability to protect and enforce intellectual property rights, the availability of financing to support future growth, competitive pressures within the verification and materials technology sectors, and economic or supply chain disruptions that could impact the industries SMX serves.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. SMX undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this editorial except as required by applicable securities laws.
Local Grand Reopening November 15, 2025 12PM – 2PM to showcase Cutting-Edge Convenience and Personalized Service in a Next-Generational Format.
LEESBURG, GEORGIA / ACCESS Newswire / November 13, 2025 / Nibble Nation, LLC, a franchisee of Little Caesars, is proud to announce the grand reopening of its Leesburg store-with a fresh design and tech-forward ordering and pickup experience that reflects the brand’s latest prototype for speed and convenience.
Little Caesars New Digital Centric Self-Serve Lobby
New Look, New Experience
Building on Little Caesars’ reputation for Hot-N-Ready® value and convenience, our Leesburg location features the brand’s proprietary Pizza Portal®, the heated, self-service mobile-order pickup station that upends traditional counter waits. Guests who order ahead using the Little Caesars app will receive a QR code or PIN, arrive at our store and retrieve their pizza from the Pizza Portal in seconds.
Guests who want to walk in will be able to select from our Hot-N-Ready offerings and quickly check themselves out using our convenient kiosks-skipping any line altogether.
Why It Matters
In an era when convenience is king, we’re delivering on the core pillars of value, quality and convenience, while staying true to our local community roots.
What Guests Can Expect
• Order ahead via the Little Caesars app, pre-pay, and say goodbye to the counter entirely.
• Arrive at the store, grab your favorites, and pay with our friendly crew member.
• All the signature favorites: Hot-N-Ready pizzas, Crazy Bread®, Caesar Wings®, and new items like Crazy Puffs®-now with faster self-service pickup.
• Friendly local service and strong community focus
• Special Grand Reopening event: November 15, 2025 with music, giveaways, $5 pizza deals, and a live demo of the portal experience.
Join Us
November 15, 2025 12PM-2PM: We invite our Leesburg community and surrounding area to come see the new experience in action: faster, smarter, still great value. Whether you order via app, website or traditional counter, you’ll enjoy the same quality ingredients-fresh-made dough, vine-ripened tomato sauce, and never-frozen cheeses-with a pickup process designed for speed.
About Nibble Nation, LLC®
Nibble Nation, LLC has been franchising Little Caesars Pizza restaurants since 2006. Operated by Anthony King this location marks the next step in bringing the brand’s most advanced store format to the Leesburg / Albany metro region, while staying committed to our local community and team members.
About Little Caesars®
Headquartered in Detroit, Michigan, Little Caesars was founded in 1959 by Mike and Marian Ilitch. Today the brand operates in each of the 50 U.S. states and 28 countries and territories. Known for its Hot-N-Ready® value, Crazy Bread® and Pizza Portal® pickup innovation, Little Caesars remains one of the fastest-growing pizza chains in the world.
NEW YORK CITY, NEW YORK / ACCESS Newswire / November 14, 2025 / E-commerce was built on speed, convenience, and volume – but not on certainty. As marketplaces grew into global giants, the one thing that never scaled with them was verifiable truth. Authenticity still depended on expert eyes, subjective judgment, and a network of verification centers that could barely keep pace with the digital economy they supported.
The world needed a new foundation, something more durable than labels, receipts, and visual inspection. It needed a way for physical goods to carry the same kind of identity that digital assets have enjoyed for years. SMX (NASDAQ:SMX) is building that missing identity layer, a molecular passport embedded directly into the materials that make up the products we buy, sell, and trade.
What emerges is a commerce ecosystem where physical objects behave like digitally verified entities. Every item becomes self-identifying. Every purchase becomes traceable. Every resale becomes trustworthy. The physical world, for the first time, starts to operate with digital clarity.
Identity Begins at Creation, Not Resale
Traditional authentication starts at the end of the supply chain, when an item reaches a marketplace or a resale platform. SMX’s system begins at the beginning. By embedding a molecular signature directly into the raw materials – leather, polymers, metals, fibers, and components – the company gives every product a birth certificate before it ever enters circulation.
Through ongoing integrations with innovation hubs like A*STAR, CETI, and Aegis Packaging, this identity layer is already being deployed where goods are designed and manufactured. The result is a global pipeline in which products travel with their own permanent resume, readable at any point in their life.
Once that molecular identity exists, verification ceases to be an interpretive act. It becomes a real-time confirmation tied to the material itself. Authentication moves from “What does this look like?” to “What does this prove?”
The Marketplace Becomes a Verification Engine
When identity is embedded at the source, online marketplaces evolve into something more powerful than listing platforms. They become trust engines. A product can be scanned the moment it enters the resale ecosystem, and the truth of its history is revealed in seconds – not through judgment or experience, but through chemistry.
Resale platforms, refurbishers, luxury markets, and third-party sellers can operate without ambiguity. The cost of manual authentication shrinks. Fraud becomes a technical dead end. And the flow of goods becomes more efficient because every item carries its own unalterable proof.
This is not a layer added on top of e-commerce. It is the infrastructure beneath it.
A New Lifecycle for Products With Memory
Once physical goods gain digital identity, their entire lifecycle transforms. A watch, a designer bag, a limited sneaker release – each can pass from one buyer to the next without losing its connection to its origin. The continuity of identity increases resale value, strengthens brand protection, and creates new economic opportunities for circular commerce.
Even categories long plagued by uncertainty can be verified at scale. Refurbished electronics. Specialty components. Artwork. Collectible goods. High-value packaging. Pharmaceuticals. Automotive parts. Any product that travels through multiple hands benefits from a system that doesn’t forget.
Circular economies thrive when memory becomes a material property.
The Business Model Behind a Verified World
SMX’s molecular identity isn’t just a security feature. It is a data network. Every scan, every resale, every confirmation becomes part of a larger ecosystem where verified information can be analyzed, monetized, and integrated into brand strategies and marketplace operations.
Manufacturers can track how their products flow through secondary markets. Platforms can certify goods instantly and reduce friction in high-volume authentication categories. Consumers can trust that what they’re buying is real, not because someone said it was – but because the object itself confirmed it.
This is not a cosmetic upgrade to e-commerce. It is the architecture for a new era in which digital identity extends beyond screens and servers into every corner of the physical world.
The Future of Commerce Has a Pulse
E-commerce was born without a reliable identity layer for physical goods. That gap now has a solution. By starting at production and following products throughout their lifespans, SMX turns authenticity into a system function rather than a matter of human judgment.
Marketplaces remain the checkpoints of global commerce, but SMX becomes the intelligence that makes those checkpoints unbreakable. Manufacturers gain protection. Platforms gain precision. Consumers gain confidence. And the global supply chain gains something it has been missing since the birth of digital trade – verifiable truth embedded at the material level.
In a world desperate for reliability, SMX isn’t just verifying what is real. It is giving the physical world a digital identity of its own.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward looking statements reflect current expectations, assumptions, and projections regarding future events involving SMX (NASDAQ: SMX), its molecular-marking technologies, and their potential applications across e-commerce, manufacturing, authentication, and global supply-chain systems. These statements are not historical facts. They involve risks, uncertainties, and variables that could cause actual results to differ materially from those expressed or implied.
Forward looking statements in this editorial include, without limitation, expectations regarding the scalability and performance of SMX’s technology in industrial manufacturing environments; anticipated adoption of molecular identity systems by e-commerce platforms, resale markets, and authentication providers; potential commercial and operational benefits for manufacturers, brands, marketplaces, and consumers; assumptions about the expansion of SMX’s partnerships with organizations such as A*STAR, CETI, and Aegis Packaging; and projections related to market demand for verifiable products, digital identity ecosystems, data-driven authentication, and circular-economy participation.
These statements also involve assumptions about broader economic and regulatory conditions, including changes in consumer trust, intellectual-property enforcement, counterfeit-prevention strategies, sustainability expectations, and the evolution of global commerce and resale platforms. Risks that could cause actual outcomes to differ materially include but are not limited to changes in market adoption, competitive technology developments, integration challenges within manufacturing workflows, supply-chain volatility, macroeconomic pressures, regulatory shifts, capital availability, and the factors described in SMX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise any forward looking statements to reflect future events, new information, or changes in assumptions, except as required by law.
NEW YORK, NY / ACCESS Newswire / November 14, 2025 / For centuries, gold has existed outside the world of modern infrastructure. Digital identity systems have evolved. Financial instruments evolved. Global logistics has evolved. Yet gold, the very foundation of sovereign reserves and private wealth, remained an analog asset defined by trust, certificates, and manual verification.
That model is finally breaking.
SMX (NASDAQ:SMX), through its majority-owned subsidiary trueGold, has introduced the first technology that allows gold to function like a verified asset inside a modern financial system. The breakthrough comes not from a database or barcode, but from the metal itself. A molecular signature is embedded directly into gold at the earliest stage of extraction. That signature stays with the material through refining, casting, vaulting, trading, and recycling. It cannot be removed or forged. It becomes part of the infrastructure that governs the asset.
This shift is not theoretical. It is now operational.
trueGold’s technology has attracted a new strategic partner: Goldstrom, a global precious-metals group with operations spanning secure logistics, vaulting, trading, bullion banking, and wealth advisory. Their collaboration integrates trueGold’s molecular certification system into Goldstrom’s operational pipelines, transforming how gold is authenticated as it moves through institutional markets.
The combination forms a new infrastructure layer for the precious-metals economy. SMX provides the science. Goldstrom provides the scale. Together, they introduce a system in which verification is continuous and embedded, rather than external or discretionary.
The Backbone of a Verified Metals Network
trueGold’s platform consists of three elements: a molecular marker, a proprietary reader, and a digital registry that records each transfer. Once added, the chemical signature inside the gold becomes a permanent identity tag. It links physical matter to digital truth.
Independent testing by Intertek confirmed the marker’s safety and neutrality under the AnchorCert Pro 2 protocol, validating compliance across the United States, Canada, and the European Union. It does not alter the metal. It does not affect purity. It does not disrupt manufacturing or design. It simply turns gold into a self-identifying asset.
That capability now enters Goldstrom’s global footprint. Every movement through Goldstrom’s vaults, logistics centers, or banking channels can be tied to verified material identity. For the first time, a bullion ecosystem can operate with intrinsic proof instead of proxy documentation.
The value becomes clear when applied at scale. Regulatory frameworks shift from assumptions to evidence. ESG claims become measurable instead of declarative. Wealth managers gain the ability to prove provenance for institutional clients. Traders can validate recycled content, purity, and custody with unprecedented precision.
In a market where trust determines price, proof-based infrastructure is not a feature. It is an advantage.
The Regulatory Signal That Changes the Sector
The London Bullion Market Association has already recognized the significance of the technology by accrediting SMX’s molecular marker as a Gold Bar Security Feature. That endorsement is more than a technical milestone. It is an indicator that the world’s largest precious-metals authority accepts molecular proof as part of the authentication process.
With Goldstrom adopting the system, the infrastructure gains a runway for global deployment. A vault in Zurich, a refinery in Dubai, or a trading house in Singapore can operate on a shared identity layer that travels with the gold itself. Compliance becomes simpler. Fraud becomes harder. Market confidence strengthens.
And the timing aligns with global demand. IBM research shows that consumers are willing to pay substantial premiums for traceable products. PwC reports measurable margin expansion for verified sustainable sourcing. Those same behavioral patterns influence how bullion is valued, particularly among institutions that must justify ESG positions or provide transparent reporting.
trueGold and Goldstrom are not asking the market to imagine a future version of accountability. They are building the infrastructure today.
The Beginning of a Verified Financial Asset Class
This partnership represents more than a technology integration. It signals the emergence of a proof-ready asset class for precious metals.
Gold has always held value. Now it can verify that value. By embedding molecular identity directly into the metal and linking that identity to a secure digital registry, SMX and trueGold convert gold from an asset that relies on external trust into one that carries trust internally. Goldstrom extends that capability across global supply lines.
What began as a scientific breakthrough at SMX is becoming a new architecture for how markets authenticate one of the world’s most important commodities. The vaults, transfers, trades, audits, and recycling streams all become synchronized through chemistry and digital certainty.
In this new model, gold does not exist solely within the financial system. It becomes part of the system’s infrastructure. Proof is no longer something attached to an asset. It is something engineered into it.
And in this case, and for the first time in its history, gold can prove itself.
About SMX
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
This editorial contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward looking statements include expectations, projections, and assumptions about future events relating to SMX (NASDAQ:SMX), its majority-owned subsidiary trueGold, its partnership with Goldstrom, and the development and commercial expansion of molecular marking, digital registries, and supply chain verification technologies within the global precious-metals sector. These statements are not descriptions of historical facts. They are based on current beliefs, estimates, and assumptions that are inherently subject to risks, uncertainties, and factors that are difficult to predict.
Forward looking statements in this editorial include, but are not limited to, expectations regarding the integration of trueGold’s molecular-marking technology into Goldstrom’s operational framework; the potential widespread adoption of SMX-enabled verification across vaulting, logistics, bullion trading, banking, and wealth management; anticipated improvements in gold authentication processes; the potential for SMX systems to be recognized or mandated by regulatory bodies, including the London Bullion Market Association and other global metals authorities; and the anticipated value that verified provenance, traceability, and lifecycle tracking may bring to market participants, investors, and institutional clients.
These statements also encompass expectations about the potential scalability of SMX technology across refineries, recycling operations, manufacturing pipelines, and international metals markets; the ability of molecular identity markers to survive refining or remelting processes; the potential to enhance ESG reporting, sustainability claims, or compliance frameworks; and the possibility of establishing new economic models built on authenticated material identity. Forward looking statements further include assumptions about evolving consumer demand for transparent and traceable products; projected economic benefits from verified material flows; and the belief that proof-driven systems may influence commodity pricing, institutional adoption, and sector-wide operational standards.
These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, but are not limited to: changes in regulatory requirements affecting precious-metals trading and authentication; fluctuations in global commodity markets; geopolitical conditions; competitive technological developments; the pace at which institutional actors adopt new verification systems; technical limitations in deploying molecular markers at industrial scale; risks associated with integrating new technologies into established supply chains; general economic conditions; and other risks detailed in SMX’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.
